Investment boost for North East firm transforming diabetic retinopathy

A company behind light-based treatment to help save diabetic patients’ sight has received six-figure investment.

PolyPhotonix has been backed to promote its Noctura 400 mask.

The covering delivers light therapy to patients suffering from diabetic retinopathy, which can cause blindness if left untreated.

Bosses say the investment, from NPIF – FW Capital Debt Finance, will also support a new Tees Valley customer service centre.

Richard Kirk, chief executive at PolyPhotonix, which has an office at Sedgefield’s NETPark, said: “The concept of the Noctura 400 is very simple.

“It’s an eye mask worn at night that delivers low-level light at your home at significantly reduced cost to the expensive eye injections and laser treatments available in hospitals.

“I’m very proud of where we are today, and the difference this product is making to diabetic patients worried about losing their eyesight.

“It’s a real game-changer and is extremely efficacious.”

Keith Charlton, fund manager at FW Capital, which manages NPIF – FW Capital Debt Finance, added: “PolyPhotonix is transforming diabetic eye care, and it’s non-invasive and cost-effective approach is benefiting both healthcare providers and patients.

“It’s an exciting time for the business as it drives forward.

“There is enormous potential for growth overseas too.

“The management team is highly experienced, and Richard is very well regarded in the sector.

“I’m delighted to help PolyPhotonix with this funding, which will help bring the Noctura 400 to more NHS healthcare providers and their patients.”